title: Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).
abstract: BACKGROUND
  High cure rates are expected in good-risk metastatic nonseminomatous germ-cell tumor (NSGCT) patients with bleomycin, etoposide and cisplatin.
  
  
  METHODS
  Patients received either three cycles of BE500P or four cycles of E500P every 3 weeks. Disease was defined according to the Institut Gustave Roussy prognostic model. Patients were retrospectively assigned into the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. A sample size of 250 patients was necessary for an expected favorable response rate (primary end point) of 90% and not more than a 10% difference between the two arms.
  
  
  RESULTS
  Among 257 assessable patients, 124 and 122 patients achieved a favorable response in the 3BE500P and 4E500P arms, respectively (P = 0.34). Median follow-up was 53 months. The 4-year event-free survival rates were 91% and 86%, respectively (P = 0.135). The 4-year overall survival rates were not significantly different [five deaths versus 12 deaths, respectively (P = 0.096)]. Similar nonsignificant trends were observed in good IGCCCG prognosis patients.
  
  
  CONCLUSIONS
  Both regimens produced similar results in terms of favorable response rates. As the trial was underpowered for survival analyses, conclusive data would require a larger randomized trial. Unless such a study is done, 3BE500P is the treatment of choice for metastatic NSGCT patients.
authors.affiliation: CRLC Val d'Aurelle, Montpellier, France. stculine@valdorel.fnclcc.fr
authors.forename: S
authors.initials: S
authors.lastname: Culine
authors.forename: P
authors.initials: P
authors.lastname: Kerbrat
authors.forename: A
authors.initials: A
authors.lastname: Kramar
authors.forename: C
authors.initials: C
authors.lastname: Théodore
authors.forename: C
authors.initials: C
authors.lastname: Chevreau
authors.forename: L
authors.initials: L
authors.lastname: Geoffrois
authors.forename: N B
authors.initials: NB
authors.lastname: Bui
authors.forename: J
authors.initials: J
authors.lastname: Pény
authors.forename: A
authors.initials: A
authors.lastname: Caty
authors.forename: R
authors.initials: R
authors.lastname: Delva
authors.forename: P
authors.initials: P
authors.lastname: Biron
authors.forename: K
authors.initials: K
authors.lastname: Fizazi
authors.forename: J
authors.initials: J
authors.lastname: Bouzy
authors.forename: J P
authors.initials: JP
authors.lastname: Droz
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000473:pathology; D012307:Risk Factors; D016019:Survival Analysis; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin